Mutant Glucocerebrosidase Impairs Α-Synuclein Degradation by Blockade of Chaperone-Mediated Autophagy.

Sheng-Han Kuo,Inmaculada Tasset,Melody M. Cheng,Antonio Diaz,Ming-Kai Pan,Ori J. Lieberman,Samantha J. Hutten,Roy N. Alcalay,Sangjun Kim,Pilar Ximenez-Embun,Li Fan,Donghoon Kim,Han Seok Ko,Talene Yacoubian,Ellen Kanter,Ling Liu,Guomei Tang,Javier Munoz,Sergio Pablo Sardi,Aiqun Li,Li Gan,Ana Maria Cuervo,David Sulzer
DOI: https://doi.org/10.1126/sciadv.abm6393
IF: 13.6
2022-01-01
Science Advances
Abstract:The most common genetic risk factors for Parkinson's disease (PD) are a set of heterozygous mutant (MT) alleles of the GBA1 gene that encodes β-glucocerebrosidase (GCase), an enzyme normally trafficked through the ER/Golgi apparatus to the lysosomal lumen. We found that half of the GCase in lysosomes from postmortem human GBA-PD brains was present on the lysosomal surface and that this mislocalization depends on a pentapeptide motif in GCase used to target cytosolic protein for degradation by chaperone-mediated autophagy (CMA). MT GCase at the lysosomal surface inhibits CMA, causing accumulation of CMA substrates including α-synuclein. Single-cell transcriptional analysis and proteomics of brains from GBA-PD patients confirmed reduced CMA activity and proteome changes comparable to those in CMA-deficient mouse brain. Loss of the MT GCase CMA motif rescued primary substantia nigra dopaminergic neurons from MT GCase-induced neuronal death. We conclude that MT GBA1 alleles block CMA function and produce α-synuclein accumulation.
What problem does this paper attempt to address?